MannKind Reports $111.96M Q4 Revenue, EPS of $0.01
MannKind reported Q4 adjusted EPS of $0.01 and revenue of $111.955 million, exceeding consensus by $14.351 million driven by royalties, collaborations and commercial product sales. The company held $74.882 million in cash at year-end and cited Furoscix’s addition to its cardiometabolic franchise as Afrezza and UT revenues grew.
1. Q4 2025 Financial Results
MannKind delivered adjusted earnings per share of $0.01 in Q4 2025, meeting consensus forecasts, while revenue climbed to $111.955 million, topping estimates by $14.351 million. Full-year 2025 revenues also rose, supported by stronger royalties, collaborations and commercial product sales.
2. Product and Franchise Highlights
Management highlighted Furoscix’s addition to the cardiometabolic portfolio as a key growth driver, alongside sustained Afrezza and UT-related revenue gains. The company ended the quarter with $74.882 million in cash and equivalents, bolstering its liquidity position for upcoming initiatives.
3. Technical Analysis and Trading Outlook
Shares currently trade 9.8% below the 20-day SMA and 4.1% below the 100-day SMA, with an RSI of 44.45 signaling neutral momentum and a bearish MACD at 0.15 versus a 0.22 signal line. Key technical levels include resistance at $4.00 and support at $2.50, suggesting cautious trading.
4. Analyst Estimates and Price Targets
Analysts forecast Q1 2026 earnings of $0.02 per share on $98.62 million in revenue, reflecting higher top-line guidance but lower profitability. The stock holds an average Buy rating with a $8.38 price target, although one firm recently trimmed its target to $8.00 ahead of the May 7 earnings release.